



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Mr. R. Vanlalruata, (Assistant Director (F and D))
Office of Chief Medical Officer, Aizwal, Mizoram-796017
2. Serial No. and date of Inspector's memorandum : 26/AZL E/2026/Local , 25-FEB-2026
3. Number of Sample : NIL
4. Date of receipt : 11-MAR-2026
5. Names of drugs purporting to be contained in the sample : Febuxostat Tablets 40 mg. (Uroxat 40 Tablets)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2026-27/0206	GUW/LS/2026-27/179	AT25090767A	Sep-2025 Aug-2027	NA	Accura Care Pharmaceuticals Pvt. Ltd., (A VENTURE OF BIOCHEMIX GROUP) Vill. Moginand, Nahan Road, Kala Amb, Dist. Sirmour (H.P.)-173030.

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 18-Jun-2026 To 24-Jun-2026

COMPOSITION : Each film coated tablet contains:
Febuxostat 40 mg

Protocol Applied : Manufacturer Specification

Sr No.	Test Name	Result	Limits
1	Description	White, round, bi-convex, scored on one surface, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Febuxostat.	NA
3	Average weight	0.1821 g	NA
4	Uniformity of weight	Complies.	+7.5 % of Average weight
5	Disintegration	Complies. (Time taken for disintegration 02 minutes 10 seconds)	NMT 30 minutes

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Febuxostat	38.71 mg/Tablet	40 mg/Tablet	96.775	90 % to 110 %	Manufacturer Specification

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per Manufacturer Specification in respect of test performed.

Date: 01-JUL-2026

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

----- END OF REPORT -----

